Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Barinthus Biotherapeutics plc - American Depositary Shares
(NQ:
BRNS
)
1.110
-0.050 (-4.30%)
Streaming Delayed Price
Updated: 11:40 AM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,922
Open
1.070
Bid (Size)
1.110 (2)
Ask (Size)
1.190 (2)
Prev. Close
1.160
Today's Range
1.070 - 1.140
52wk Range
0.8008 - 4.159
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
November 25, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Performance
YTD
-70.00%
-70.00%
1 Month
+13.93%
+13.93%
3 Month
-7.49%
-7.49%
6 Month
-15.90%
-15.90%
1 Year
-68.46%
-68.46%
More News
Read More
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
November 15, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
November 15, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
November 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
October 31, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
October 01, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
August 08, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
August 01, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
June 21, 2024
Via
Benzinga
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
June 12, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 05, 2024
Via
Benzinga
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
May 22, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 01, 2024
Via
Benzinga
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 30, 2024
Via
Benzinga
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
April 19, 2024
Via
Benzinga
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
April 18, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
April 03, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.